Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 4:23 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2833–2856 of 14,161 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Safety Control Clear all
Completed Phase 3 Interventional Results available

A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 Inhibitor

NCT06109311
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Orforglipron, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
546 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
25
States / cities
Chandler, Arizona • Phoenix, Arizona • Bryant, Arkansas + 22 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Nov 13, 2026, 4:23 AM EST
Completed Phase 2 Interventional Results available

Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Moderate to Severe Acne Vulgaris With Photodynamic Therapy in Adults

NCT05080764
View directory record Official record
Conditions
Acne Vulgaris
Interventions
1h Incubation Photodynamic therapy (PDT) (ALA-PDT, Ameluz®-PDT), 1h Incubation Photodynamic therapy (PDT) (vehicle to BF-200 ALA containing no active ingredient), 3h Incubation Photodynamic therapy (PDT) (ALA-PDT, Ameluz®-PDT), 3h Incubation Photodynamic therapy (PDT) (vehicle to BF-200 ALA containing no active ingredient)
Combination Product
Lead sponsor
Biofrontera Inc.
Industry
Eligibility
16 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
9
States / cities
Fountain Valley, California • San Diego, California • Delray Beach, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Nov 13, 2026, 4:23 AM EST
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Dasotraline in Children 6 to 12 Years of Age With Attention-Deficit Hyperactivity Disorder (ADHD) in a Simulated Classroom Setting.

NCT02734693
View directory record Official record
Conditions
Attention-Deficit Hyperactivity Disorder (ADHD)
Interventions
dasotraline 4mg, Placebo
Drug · Other
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
6 Years to 12 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
5
States / cities
Newport Beach, California • Bradenton, Florida • Maitland, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2020 · Synced Nov 13, 2026, 4:23 AM EST
Completed Phase 2 Interventional Results available

Efficacy and Safety of BB-12 Supplemented Strawberry Yogurt For Healthy Children on Antibiotics

NCT03181516
View directory record Official record
Conditions
Antibiotic-associated Diarrhea
Interventions
Bifidobacterium animalis subsp. lactis BB-12, Control
Biological · Other
Lead sponsor
Georgetown University
Other
Eligibility
3 Years to 12 Years
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Feb 21, 2025 · Synced Nov 13, 2026, 4:23 AM EST
Not listed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety of SAB-176 to Prevent the Flu, Given IM in Healthy Adults Compared With Placebo

NCT06435936
View directory record Official record
Conditions
PHA1A
Interventions
Single Ascending Dose of SAB-176, Single Ascending Dose of Placebo
Drug
Lead sponsor
SAb Biotherapeutics, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Nov 13, 2026, 4:23 AM EST
Active, not recruiting Not applicable Interventional

Generative AI Patient Education Module for Breast Oncology

NCT07512271
View directory record Official record
Conditions
Breast Cancer, Metastatic Breast Cancer, Carcinoma of the Breast
Interventions
Survey (Participant), OpenEvidence CareConnect, Survey (Provider)
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 12, 2026 · Synced Nov 13, 2026, 4:23 AM EST
Completed Phase 1 Interventional

A Study to Evaluate the Safety of mRNA-0184 in Participants With Heart Failure

NCT05659264
View directory record Official record
Conditions
Chronic Heart Failure
Interventions
mRNA-0184, Placebo
Drug
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
5
States / cities
Birmingham, Alabama • Gainesville, Florida • Jacksonville, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2025 · Synced Nov 13, 2026, 4:23 AM EST
Completed Phase 3 Interventional Results available

An Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment

NCT01064414
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Renal Insufficiency
Interventions
Canagliflozin, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
25 Years and older
Enrollment
272 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
26
States / cities
Concord, California • Fountain Valley, California • San Diego, California + 23 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2013 · Synced Nov 13, 2026, 4:23 AM EST
Completed Phase 3 Interventional Results available

An Evaluation of the Efficacy and Safety of CSF-1 in the Temporary Correction of Presbyopia (NEAR-1)

NCT04599933
View directory record Official record
Conditions
Presbyopia
Interventions
CSF-1, Vehicle
Drug
Lead sponsor
Orasis Pharmaceuticals Ltd.
Industry
Eligibility
45 Years to 64 Years
Enrollment
309 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
17
States / cities
Sun City, Arizona • Glendale, California • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2024 · Synced Nov 13, 2026, 4:23 AM EST
Completed Phase 2 Interventional

Study to Assess the Efficacy, Safety, and Tolerability of AZD8529 in Adult Schizophrenia Patients

NCT00921804
View directory record Official record
Conditions
Schizophrenia
Interventions
AZD 8529, Risperidone, Placebo to match AZD8529, Placebo to match risperidone
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
296 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
3
States / cities
Garden Grove, California • Glendale, California • Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 30, 2010 · Synced Nov 13, 2026, 4:23 AM EST
Terminated Phase 2 Interventional

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ACH-0137171 in Participants With Chronic Hepatitis C Infection

NCT00401947
View directory record Official record
Conditions
HCV Infection
Interventions
ACH-0137171
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
7
States / cities
Phoenix, Arizona • La Jolla, California • San Francisco, California + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2022 · Synced Nov 13, 2026, 4:23 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Pharmacokinetics and Acceptability of PC-1005 for Vaginal Use

NCT02033109
View directory record Official record
Conditions
HIV
Interventions
PC-1005, HEC gel
Drug
Lead sponsor
Population Council
Other
Eligibility
19 Years to 49 Years · Female only
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 15, 2017 · Synced Nov 13, 2026, 4:23 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety, Tolerability and Pharmacokinetics of Escalating Single Doses of ENV8058 (TAK-058) in Healthy Participants

NCT02153099
View directory record Official record
Conditions
Dose Finding Study
Interventions
TAK-058 (ENV8058), Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Dec 17, 2015 · Synced Nov 13, 2026, 4:23 AM EST
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of LymphoStat-B (Belimumab) in Subjects With Systemic Lupus Erythematosus (SLE)

NCT00071487
View directory record Official record
Conditions
Lupus Erythematosus, Systemic
Interventions
Placebo, Belimumab 1 mg/kg, Belimumab 4 mg/kg, Belimumab 10 mg/kg
Drug
Lead sponsor
Human Genome Sciences Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
449 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
60
States / cities
Birmingham, Alabama • Paradise Valley, Arizona • Tucson, Arizona + 52 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2013 · Synced Nov 13, 2026, 4:23 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the Abuse Liability Potential of Samidorphan in Healthy, Non-Dependent, Recreational Opioid Users

NCT02218021
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Samidorphan, Placebo, Oxycodone
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Dec 2, 2014 · Synced Nov 13, 2026, 4:23 AM EST
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Darolutamide (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer

NCT02200614
View directory record Official record
Conditions
Prostate Cancer Non-Metastatic, Castration-Resistant
Interventions
Darolutamide (Nubeqa, BAY1841788), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Male only
Enrollment
1,509 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
55
States / cities
Homewood, Alabama • Anchorage, Alaska • Tucson, Arizona + 48 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2022 · Synced Nov 13, 2026, 4:23 AM EST
Completed Phase 3 Interventional

Study of Cariprazine Oral Capsules or Solution to Assess Adverse Events and Change in Irritability Due to Autism Spectrum Disorder (ASD) in Participants Aged 5-17 Years With ASD

NCT05439616
View directory record Official record
Conditions
Autism Spectrum Disorder
Interventions
Cariprazine, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
5 Years to 17 Years
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
34
States / cities
Anaheim, California • Imperial, California • Orange, California + 28 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2025 · Synced Nov 13, 2026, 4:23 AM EST
Recruiting Phase 1 Interventional

Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Subjects With Limbal Stem Cell Deficiency

NCT06452316
View directory record Official record
Conditions
Limbal Stem Cell Deficiency
Interventions
CSB-001 Ophthalmic Solution 0.1%
Biological
Lead sponsor
Claris Biotherapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
6
States / cities
Loma Linda, California • Carmel, Indiana • Indianapolis, Indiana + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Nov 13, 2026, 4:23 AM EST
Terminated Phase 2 Interventional

Study in Adult Asthmatic Patients With Allergic Bronchopulmonary Aspergillosis

NCT03960606
View directory record Official record
Conditions
Allergic Bronchopulmonary Aspergillosis
Interventions
PUR1900, Placebo
Combination Product
Lead sponsor
Pulmatrix Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
9
States / cities
Denver, Colorado • New Haven, Connecticut • Hialeah, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2021 · Synced Nov 13, 2026, 4:23 AM EST
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Safety, Tolerability, Pharmacokinetics, and Preliminary Pharmacodynamics of QBW251 in Healthy Subjects and Cystic Fibrosis Patients

NCT02190604
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Placebo, QBW251
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
153 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
9
States / cities
Birmingham, Alabama • Denver, Colorado • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2020 · Synced Nov 13, 2026, 4:23 AM EST
Recruiting Phase 2 Interventional

Treatment of Neonatal Encephalopathy With Oral Sildenafil Suspension to Repair Brain Injury Secondary to Birth Asphyxia

NCT06098833
View directory record Official record
Conditions
Neonatal Encephalopathy
Interventions
Sildenafil, Ora-Blend
Drug
Lead sponsor
Pia Wintermark
Other
Eligibility
0 Minutes to 48 Hours
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Nov 13, 2026, 4:23 AM EST
Completed Phase 2 Interventional Results available

Study of ARO-ANG3 in Adults With Mixed Dyslipidemia

NCT04832971
View directory record Official record
Conditions
Mixed Dyslipidemia
Interventions
ARO-ANG3, Placebo
Drug
Lead sponsor
Arrowhead Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
13
States / cities
Huntington Park, California • Hialeah, Florida • Miami, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2025 · Synced Nov 13, 2026, 4:23 AM EST
Not listed Phase 2 Interventional

Safety, Tolerability, and Efficacy of Arbaclofen in 16p11.2 Deletion

NCT04271332
View directory record Official record
Conditions
16P11.2 Deletion Syndrome
Interventions
Arbaclofen, Placebo oral tablet
Drug
Lead sponsor
Clinical Research Associates, LLC
Other
Eligibility
5 Years to 17 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
4
States / cities
Boston, Massachusetts • New York, New York • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated May 30, 2024 · Synced Nov 13, 2026, 4:23 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate Safety, Tolerability, and Pharmacokinetics (PK) of VH4524184 and the Potential for Changes in Cytochrome P450 3A (CYP3A) Activity

NCT05631704
View directory record Official record
Conditions
HIV Infections
Interventions
VH4524184, Midazolam, Placebo
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 50 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 29, 2025 · Synced Nov 13, 2026, 4:23 AM EST